On the Clinical Frontier of Gene Editing
Who We Are
CorriXR Therapeutics is an oncology-focused biotherapeutics development company with a ground-breaking gene editing platform technology.
CorriXR Therapeutics is the inaugural biotech spin-out of ChristianaCare, a large healthcare system, and the Gene Editing Institute, which has been embedded in ChristianaCare’s Helen F. Graham Cancer Center & Research Institute since 2015.
What We’re Doing
We have developed a broad-based gene editing platform that utilizes a unique CRISPR/Cas biomolecular tool to specifically disable a gene in tumor cells and not healthy cells. We are laser-focused on our initial target for the treatment of squamous cell carcinoma of the lung. Additionally, our platform technology can be used in a multitude of solid tumors including lung, esophageal, head and neck, ovarian, bladder, melanoma, and thyroid cancers. The CorriXR delivery system is a proprietary lipid nanoparticle (LNP) approach that will evolve from direct injection into systemic delivery for other targets.
Where We Are
We’ve met our first drug development milestone with a positive FDA INTERACT meeting. The FDA requested that we strongly consider a basket trial to include lung, esophageal, and head and neck squamous cell carcinoma.
…In addition, please provide a rationale for limiting your phase 1 study to squamous cell lung cancer. A brief literature search suggests that there is some evidence to suggest that the KEAP1-NRF2 pathway is involved in the pathogenesis of various other types of tumors…
FDA INTERACT Meeting
Meet Our Team Members
Get to know our leadership team.